# Novo Nordisk

> Danish pharmaceutical company

**Wikidata**: [Q818846](https://www.wikidata.org/wiki/Q818846)  
**Wikipedia**: [English](https://en.wikipedia.org/wiki/Novo_Nordisk)  
**Source**: https://4ort.xyz/entity/novo-nordisk

## Summary
Novo Nordisk is a Danish pharmaceutical company and public company founded on January 1, 1923. Headquartered in Bagsværd, a suburb of Copenhagen, the organization operates as an enterprise within the pharmaceutical industry, developing, producing, and marketing drugs. It is listed on both the New York Stock Exchange and Nasdaq Copenhagen A/S.

## Key Facts
- **Inception:** January 1, 1923
- **Headquarters:** Bagsværd, Denmark (suburb of Copenhagen)
- **Legal Status:** Public company
- **Stock Exchanges:** New York Stock Exchange, Nasdaq Copenhagen A/S
- **Parent Organizations:** Novo Holdings, Novo Nordisk Foundation
- **Subsidiaries:** Novo Nordisk s.r.o. (Czech business, established January 1, 1997; headquartered in Prague)
- **Key Founders/Key People:** Hans Christian Hagedorn, August Krogh, Marie Krogh
- **Affiliated Scientists:** Lotte Bjerre Knudsen, Fred Ramsdell
- **Affiliations:** C40 Cities Climate Leadership Group
- **Sports Team:** Team Novo Nordisk (cycling team, established 2008)
- **Website:** https://www.novonordisk.com
- **Reported Revenue Figures:** 126,946,000,000; 176,954,000,000; 290,403,000,000; 232,261,000,000; 309,064,000,000
- **Reported Net Profit Figures:** 42,138,000,000; 55,525,000,000; 83,683,000,000; 100,988,000,000; 102,434,000,000
- **Reported Total Assets:** 144,922,000,000; 241,257,000,000; 314,486,000,000; 465,795,000,000; 542,902,000,000
- **Employee Counts:** 42,446; 55,185; 64,319; 74,156; 68,794

## FAQs
**Where is Novo Nordisk headquartered?**
The company is headquartered in Bagsværd, a suburb of Copenhagen, Denmark. It also operates a subsidiary, Novo Nordisk s.r.o., in Prague, Czech Republic.

**Who owns Novo Nordisk?**
Novo Nordisk is owned and operated by Novo Holdings, a Danish company established in 1999, and the Novo Nordisk Foundation, an enterprise foundation established in 1989.

**What stock exchanges is Novo Nordisk listed on?**
The company is listed on the New York Stock Exchange (an American stock exchange established in 1792) and Nasdaq Copenhagen A/S (a stock exchange located in Copenhagen, Denmark).

**What types of medications does Novo Nordisk produce?**
The company produces pharmaceutical drugs including semaglutide, liraglutide, insulin detemir, insulin degludec, and insulin aspart. It also works with glucagon-like peptide-1 agonists, glucagon, growth hormone, and sex steroids.

**Is Novo Nordisk involved in sports or environmental initiatives?**
Yes, the company sponsors Team Novo Nordisk, a cycling team established in 2008. It is also affiliated with the C40 Cities Climate Leadership Group, a network of cities focused on climate action.

## Why It Matters
Novo Nordisk plays a critical role in the global healthcare landscape, particularly in the treatment of chronic conditions such as type 2 diabetes and obesity. Its development of glucagon-like peptide-1 agonists and various insulin analogues addresses widespread medical needs. The company's significant financial scale, evidenced by its multi-billion dollar revenue and asset figures, allows for substantial investment in pharmaceutical innovation. Furthermore, its unique ownership structure under the Novo Nordisk Foundation ensures that profits are often reinvested into long-term scientific and humanitarian goals rather than distributed solely to private shareholders.

## Notable For
- Development and marketing of semaglutide and liraglutide, key medications in the treatment of type 2 diabetes and obesity.
- Production of specific insulin formulations: insulin detemir, insulin degludec (an ultralong-acting basal insulin analogue), and insulin aspart.
- Founding history involving notable Danish scientists Hans Christian Hagedorn, August Krogh, and Marie Krogh.
- Operation of Team Novo Nordisk, a professional cycling team.
- High-volume financial performance with reported revenues exceeding 300 billion and net profits exceeding 100 billion in recent reported figures.

## Body

### History and Founding
Novo Nordisk was established on January 1, 1923. The company's origins are closely tied to prominent Danish figures including Hans Christian Hagedorn, a physician; August Krogh, a physiologist; and Marie Krogh, a physician and physiologist. These individuals were instrumental in the early development of the company's focus on diabetes care and hormonal treatments.

### Corporate Structure and Ownership
As a public company, Novo Nordisk offers its securities for sale to the general public. It operates as an enterprise with autonomy in resource allocation. The company is ultimately owned and operated by Novo Holdings, a Danish company founded on September 8, 1999, and the Novo Nordisk Foundation, an enterprise foundation founded on January 12, 1989. The foundation and holding company are headquartered in Denmark.

### Operations and Locations
The company's headquarters is situated in Bagsværd, a suburb of Copenhagen, Denmark. Novo Nordisk also owns or operates Hvidøre, a former country house located at Klampenborg, north of Copenhagen. Internationally, the company maintains a subsidiary known as Novo Nordisk s.r.o. This Czech business was established on January 1, 1997, and is headquartered in Prague.

### Financial Performance
Novo Nordisk demonstrates significant financial scale within the pharmaceutical industry. Reported revenue figures include 126,946,000,000; 176,954,000,000; 290,403,000,000; 232,261,000,000; and 309,064,000,000. The company's reported net profit figures are 42,138,000,000; 55,525,000,000; 83,683,000,000; 100,988,000,000; and 102,434,000,000. Total assets have been reported as 144,922,000,000; 241,257,000,000; 314,486,000,000; 465,795,000,000; and 542,902,000,000. The workforce has fluctuated over time with reported employee counts of 42,446; 55,185; 64,319; 74,156; and 68,794.

### Products and Therapeutic Areas
Novo Nordisk operates within the pharmaceutical industry, focusing on the development, production, and marketing of drugs. Key therapeutic areas include:
*   **Diabetes and Obesity:** The company produces glucagon-like peptide-1 (GLP-1) agonists, which are used in the treatment of type 2 diabetes and obesity. Notable medications in this category include semaglutide and liraglutide.
*   **Insulin Products:** The company manufactures several insulin analogues, including insulin detemir, insulin degludec (an ultralong-acting basal insulin analogue), and insulin aspart.
*   **Hormones:** Novo Nordisk deals with mammalian peptide hormones such as glucagon and growth hormones that stimulate growth, cell reproduction, and cell regeneration. It also works with sex steroids.

### Affiliations and Community
Novo Nordisk maintains affiliations with various organizations and initiatives. It is a member of the C40 Cities Climate Leadership Group, a network of cities committed to addressing climate change. In the sports sector, the company owns and operates Team Novo Nordisk, a cycling team established in 2008.

### Key People and Science
The company is associated with several key scientific figures. Lotte Bjerre Knudsen, a Danish scientist and university teacher born in 1964, is affiliated with the company. Additionally, Fred Ramsdell, an American immunologist, is listed as an affiliated person. The company's historical foundation is built upon the work of Hans Christian Hagedorn, August Krogh, and Marie Krogh.

## References

1. [Source](https://www.lobbyfacts.eu/datacard/novo-nordisk-a-s?rid=29570313329-11)
2. [annual report](https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2024/novo-nordisk-annual-report-2023.pdf)
3. [Source](http://www.novonordisk.com/about-novo-nordisk/management/executive_management/lars-fruergaard-jorgensen.html)
4. [Source](http://borsen.dk/nyheder/virksomheder/artikel/1/330767/lars_rebien_stopper_som_topchef_i_novo_nordisk_-_afloeseren_er_intern.html)
5. [Source](https://datacvr.virk.dk/data/visenhed?enhedstype=person&id=4003990636)
6. Virtual International Authority File
7. [Source](http://www.novonordisk.com/investors/Shareinformation.html)
8. [Source](https://www.c40.org/funders-partners/)
9. Freebase Data Dumps. 2013
10. Czech National Authority Database
11. [Source](https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2017/20170207_Novo%20Nordisk%20%C3%85rsskrift%202016.pdf)
12. [Source](https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2023/novo-nordisk-annual-report-2022.pdf)
13. [Source](https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2024/novo-nordisk-annual-report-2023.pdf)
14. [Source](https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2025/novo-nordisk-annual-report-2024.pdf)
15. [Source](https://ml-eu.globenewswire.com/Resource/Download/7c7c1d6f-42c0-4e8f-821c-93ff9a0858c0)
16. [Source](https://datacvr.virk.dk/enhed/virksomhed/24256790)
17. [Source](https://datacvr.virk.dk/data/visenhed?enhedstype=virksomhed&id=21093106)
18. [Source](https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2021/Novo-Nordisk-Annual-Report-2020.pdf)
19. GRID Release 2015-12-14
20. GRID Release 2016-12-06
21. GRID Release 2017-01-10
22. [Source](https://golden.com/wiki/Novo_Nordisk-PBAJ85)
23. YouTube API
24. [Novo Nordisk Company Culture | Comparably](https://www.comparably.com/companies/novo-nordisk)